Burning Rock Biotech (NASDAQ:BNR – Get Free Report) and DeFi Technologies (NASDAQ:DEFT – Get Free Report) are both small-cap business services companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, risk, institutional ownership, profitability, valuation and earnings.
Analyst Recommendations
This is a breakdown of current recommendations and price targets for Burning Rock Biotech and DeFi Technologies, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Burning Rock Biotech | 1 | 0 | 0 | 0 | 1.00 |
| DeFi Technologies | 1 | 0 | 3 | 0 | 2.50 |
DeFi Technologies has a consensus price target of $4.50, indicating a potential upside of 316.67%. Given DeFi Technologies’ stronger consensus rating and higher possible upside, analysts clearly believe DeFi Technologies is more favorable than Burning Rock Biotech.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Burning Rock Biotech | -22.33% | -21.26% | -14.27% |
| DeFi Technologies | 23.89% | 105.69% | 6.92% |
Institutional and Insider Ownership
30.0% of Burning Rock Biotech shares are owned by institutional investors. 30.3% of Burning Rock Biotech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Risk and Volatility
Burning Rock Biotech has a beta of 1.25, meaning that its share price is 25% more volatile than the S&P 500. Comparatively, DeFi Technologies has a beta of 4.34, meaning that its share price is 334% more volatile than the S&P 500.
Valuation & Earnings
This table compares Burning Rock Biotech and DeFi Technologies”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Burning Rock Biotech | $70.67 million | 3.56 | -$47.49 million | ($1.66) | -14.10 |
| DeFi Technologies | $40.30 million | 10.34 | -$28.49 million | $0.05 | 21.60 |
DeFi Technologies has lower revenue, but higher earnings than Burning Rock Biotech. Burning Rock Biotech is trading at a lower price-to-earnings ratio than DeFi Technologies, indicating that it is currently the more affordable of the two stocks.
Summary
DeFi Technologies beats Burning Rock Biotech on 11 of the 14 factors compared between the two stocks.
About Burning Rock Biotech
Burning Rock Biotech Limited primarily develops and commercializes cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its principal products include OncoCompass IO, a corresponding test for liquid biopsy samples; OncoScreen IO, a pan-cancer test for tissue samples; and OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC. In addition, the company provides ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal cancers; and brPROPHET, a pre-operative ctDNA detection and post-operative MRD calling for relapsed patients. Further, it has development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; licensing agreement with Oncocyte Corporation to in-license DetermaRx, a risk stratification test for early stage lung cancer patients in China; and collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, and IMPACT Therapeutics and Merck KGaA. Additionally, the company offers OncoMaster, an automatic NGS data analysis and report interpretation machine for in-hospital model. Burning Rock Biotech Limited was incorporated in 2014 and is headquartered in Guangzhou, China.
About DeFi Technologies
DeFi Technologies, Inc. engages in the provision of investment services. It plans to acquire equity, debt, or other securities of publicly traded or private companies or other entities. The firm offers DeFi ETNs, DeFi Governance, DeFi Venture and DeFi Treasury. The company was founded by Olivier Francois Roussy Newton and Wouter Witvoet on April 14, 1986 and is headquartered in Toronto, Canada.
Receive News & Ratings for Burning Rock Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Burning Rock Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
